Viropharma (VPHM) Shares Sink Amid Cinryze Data; Stifel Nicolaus Weighs In

March 6, 2012 12:46 PM EST Send to a Friend
Get Alerts VPHM Hot Sheet
Price: $49.96 --0%

Rating Summary:
    7 Buy, 13 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 3 | Down: 17 | New: 2
Trade VPHM Now!
Join SI Premium – FREE
Shares of Viropharma (Nasdaq: VPHM) have tumbled nearly 7 percent Tuesday following the release of data on the company's subcutaneous Cinryze(R) with recombinant human hyaluronidase. The stock last traded at $30.50.

Stifel Nicolaus' Stephen Willey said in an earlier note Viropharma will likely need to show more dose-ranging data on the product's effectiveness. While the analyst noted 2,000-unit sub-Q data validates utilization of rHuPH20 usage with Cinryze, he warned logistical issues may pop up related to manufacturing capacity and cost before a twice-per-week dosing could be a feasible option. Willey also suggested the data confirms an unformulated sub-Q1 C1 inhibitor would not be a viable treatment option.

Despite the cautious comments, Stifel Nicolaus and Willey maintain a Buy rating and $42 price target on shares of Viropharma.

Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Viropharma.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Corporate News

Related Entities

Stifel Nicolaus

Add Your Comment